AstraZeneca Pharma India will be launching Osimertinib 40 mg and 80 mg (Tagrisso) in India on July 27, 2017. Osimertinib 40 mg and 80 mg (Tagrisso) is an oral anti-cancer drug for management of lung cancer.
It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy. Osimertinib (Tagrisso) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
